SCHEMBL1422698

SCHEMBL1422698

Fc1ccc(-c2nc(-c3ccc4nccn4c3)no2)cn1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 2/20 0.49
HDAC6 Q9UBN7 2/20 0.49
HDAC8 Q9BY41 1/20 0.49
DYRK1A Q13627 3/20 0.44
JAK2 O60674 1/20 0.44
RET P07949 1/20 0.44
KDR P35968 1/20 0.44
GSK3A P49840 1/20 0.44
RPS6KA3 P51812 1/20 0.44
LIMK1 P53667 1/20 0.44
MAP2K1 Q02750 1/20 0.44
MAPK14 Q16539 1/20 0.44
CLK4 Q9HAZ1 1/20 0.44
ALK Q9UM73 1/20 0.44
DYRK1B Q9Y463 1/20 0.44
ALOX5AP P20292 1/20 0.43
HDAC5 Q9UQL6 1/20 0.40
TGFBR1 P36897 6/20 0.39
CPT2 P23786 1/20 0.39
CPT1A P50416 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3678631 0.85 NPC1 (0.48) HDAC1HDAC6HDAC8DYRK1AALOX5AP
SCHEMBL1422810 0.82 CHRNB2 (0.61) S1PR1CHRNB2CHRNA5CHRNA4
SCHEMBL1422635 0.82 HDAC1 (0.45) HDAC1HDAC6HDAC8DYRK1AJAK2
SCHEMBL29379493 0.76 HDAC6 (0.67) HDAC1HDAC6HDAC8DYRK1AHDAC5
SCHEMBL12619117 0.69 S1PR1 (0.61) HDAC1HDAC6HDAC8S1PR1
SCHEMBL20390778 0.68 AOC3 (0.44) ALOX5APS1PR1
SCHEMBL14826052 0.67 DYRK1A (0.85) DYRK1ARETTGFBR1MCHR1PIK3CA
SCHEMBL1830448 0.67 DYRK1A (0.71) DYRK1AJAK2RETTGFBR1MCHR1
SCHEMBL19745815 0.66 HDAC6 (1.00) HDAC1HDAC6HDAC8HDAC5
SCHEMBL30639453 0.66 DYRK1A (0.63) DYRK1AJAK2RETKDRGSK3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9040568-B2 Pharmaceutical compositions for the treatment of pain ABBVIE INC. (US) 2015-05-26 US claimed
EP-2297140-A1 NOVEL 1,2,4 OXADIAZOLE COMPOUNDS AND METHODS OF USE THEREOF Abbott Laboratories (US) 2011-03-23 EP claimed
WO-2010138600-A2 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAIN ABBOTT LABORATORIES (US) 2010-12-02 WO claimed
US-20100305086-A1 Pharmaceutical Compositions for the Treatment of Pain ABBOTT LABORATORIES (US) 2010-12-02 US claimed
WO-2009148452-A1 NOVEL 1,2,4 OXADIAZOLE COMPOUNDS AND METHODS OF USE THEREOF ABBOTT LABORATORIES (US) 2009-12-10 WO claimed
US-20080269236-A1 Novel 1,2,4 Oxadiazole Compounds and Methods of Use Thereof ABBOTT LABORATORIES (US) 2008-10-30 US claimed
US-9040568-B2 Pharmaceutical compositions for the treatment of pain ABBVIE INC. (US) 2015-05-26 US disclosed
US-8486979-B2 Analgesics; central nervous system disorders; attentiondeficit disorders;cognition activators; bipolar disorders; Alzheimer's disease; Down's syndrome; brain disorders ABBVIE INC. (US) 2013-07-16 US disclosed
US-20100305086-A1 Pharmaceutical Compositions for the Treatment of Pain ABBOTT LABORATORIES (US) 2010-12-02 US disclosed
US-20080269236-A1 Novel 1,2,4 Oxadiazole Compounds and Methods of Use Thereof ABBOTT LABORATORIES (US) 2008-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305086-A1 Pharmaceutical Compositions for the Treatment of Pain CHRNA1, CHRNG, CHRNA4 HDAC1 2548/4885HDAC6 1099/4885HDAC8 2646/4885
US-20080269236-A1 Novel 1,2,4 Oxadiazole Compounds and Methods of Use Thereof OXA1L, CYP11B2, CYP1B1 HDAC1 892/4885HDAC6 308/4885HDAC8 2283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.